ATRA Stock Recent News
ATRA LATEST HEADLINES
Late last week, Atara Biotherapeutics Inc (NASDAQ: ATRA) announced that Bayer AG (OTC: BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The.
Benzinga 2022 May 23
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research 2022 May 05